Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

AZ 628

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AstraZeneca

Drug class:

pan-RAF inhibitor

Related drugs:

KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	AZ 628 Resistant: D – Preclinical AZ 628 Resistant : D	AZ 628 Resistant: D – Preclinical AZ 628 Resistant : D
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	selumetinib + AZ 628 Sensitive: D – Preclinical selumetinib + AZ 628 Sensitive : D	selumetinib + AZ 628 Sensitive: D – Preclinical selumetinib + AZ 628 Sensitive : D
NRAS mutation	Endometrial Cancer	NRAS mutation	Endometrial Cancer	AZ 628 Sensitive: D – Preclinical AZ 628 Sensitive : D	AZ 628 Sensitive: D – Preclinical AZ 628 Sensitive : D
HRAS mutation	Endometrial Cancer	HRAS mutation	Endometrial Cancer	AZ 628 Sensitive: D – Preclinical AZ 628 Sensitive : D	AZ 628 Sensitive: D – Preclinical AZ 628 Sensitive : D
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	AZ 628 Sensitive: D – Preclinical AZ 628 Sensitive : D	AZ 628 Sensitive: D – Preclinical AZ 628 Sensitive : D
NF1 deletion	Melanoma	NF1 deletion	Melanoma	trametinib + AZ 628 Sensitive: D – Preclinical trametinib + AZ 628 Sensitive : D	trametinib + AZ 628 Sensitive: D – Preclinical trametinib + AZ 628 Sensitive : D
BRAF V600E	Thyroid Gland Carcinoma	BRAF V600E	Thyroid Gland Carcinoma	AZ 628 Sensitive: D – Preclinical AZ 628 Sensitive : D	AZ 628 Sensitive: D – Preclinical AZ 628 Sensitive : D
BRAF delNVTAP	Pancreatic Cancer	BRAF delNVTAP	Pancreatic Cancer	AZ 628 Sensitive: D – Preclinical AZ 628 Sensitive : D	AZ 628 Sensitive: D – Preclinical AZ 628 Sensitive : D
BRAF V600E	Pancreatic Cancer	BRAF V600E	Pancreatic Cancer	AZ 628 Sensitive: D – Preclinical AZ 628 Sensitive : D	AZ 628 Sensitive: D – Preclinical AZ 628 Sensitive : D